Panther Biotechnology Announces New Drug Candidate to Selectively Kill Leukemia Stem Cells

Under the terms of the agreement, Panther has licensed from the University of Rochester, the rights to develop and commercialize a first in class new chemical entity with demonstrated powerful anti-leukemia activity. The licensed compound, called TDZD-8, is a small molecule engineered to kill leukemic stem cells.

http://ift.tt/1cCm1iU